Weichung "Joe" Shih, Ph.D.
SPH Building Room: 216
Dr. Shih is a member of the Editorial Boards of the Society for Clinical Trials, the Journal of Statistics in Biopharmaceutical Research, Statistics in Medicine, Statistica Sinica, and the Journal of Clinical Cancer Research.
2002 Excellence in Teaching Award, The Student Government Association, School of Public Health
1996 Elected American Statistical Association (ASA) Fellow
Luo X, Shih WJ, Ouyang SP, Delap RJ. An optimal adaptive design to address local regulations in global clinical trials. Pharm Stat. 2010 Jul;9(3):179-89.
Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010 Jul 1;16(13):3299-318.
Liu J, Lin Y, Shih WJ. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution. Stat Med. 2010 May 10;29(10):1084-95.
Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, Shih WJ, Huang MT, Liu Y, Rabson A, Reddy B, Yang CS, Conney AH. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila). 2010 Jan;3(1):114-24.
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA. 2009 Sep 16;302(11):1202-9.
Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3. Epub 2009 Aug 27.
Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res. 2009 Jun 1;15(11):3896-902. Epub 2009 May 19.
Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. Pediatrics. 2009 May;123(5):e770-6.
Lu-Yao G, Albertsen P, Shih W, Yao SL. Failure to report financial disclosure information. JAMA. 2009 Jan 7;301(1):35-6. No abstract available.
Wu Y, Shih WJ. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design. Stat Med. 2008 Dec 20;27(29):6190-208.
Lu YP, Lou YR, Xie JG, Peng Q, Shih WJ, Lin Y, Conney AH. Tumorigenic effect of some commonly used moisturizing creams when applied topically to UVB-pretreated high-risk mice. J Invest Dermatol. 2009 Feb;129(2):468-75. Epub 2008 Aug 14.